SCHEMBL2882283

SCHEMBL2882283

Nc1c(F)c(Cc2ccccc2)c(N)c(Cc2ccccc2)c1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CALM1 P0DP23 1/20 0.46
ALDH1A1 P00352 2/20 0.37
LOXL2 Q9Y4K0 2/20 0.37
MAOA P21397 2/20 0.37
MAOB P27338 2/20 0.37
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
HTR2A P28223 2/20 0.36
LTB4R Q15722 1/20 0.36
AOC3 Q16853 1/20 0.36
PLA2G10 O15496 1/20 0.35
PLA2G2A P14555 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35
CA13 Q8N1Q1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2960873 0.84 CALM1 (0.58) CALM1ALDH1A1LOXL2MAOAMAOB
SCHEMBL28381844 0.83 CALM1 (0.42) CALM1ALDH1A1LOXL2MAOAMAOB
SCHEMBL11826767 0.79 CALM1 (0.52) CALM1ALDH1A1LOXL2MAOAMAOB
SCHEMBL23300527 0.77 HTR2A (0.42) CALM1MEN1KMT2AHTR2ASMN1; SMN2
SCHEMBL15104760 0.77 CALM1 (0.55) CALM1ALDH1A1LOXL2MAPT
SCHEMBL27263739 0.75 MEN1 (0.49) CALM1ALDH1A1MEN1LMNAGAA
SCHEMBL6069475 0.74 CALM1 (0.41) CALM1ALDH1A1LOXL2MAOAMAOB
SCHEMBL11901755 0.74 CALM1 (0.41) CALM1ALDH1A1LOXL2MAOAMAOB
SCHEMBL12432588 0.73 CALM1 (0.50) CALM1ALDH1A1LOXL2MAOAMAOB
SCHEMBL2820256 0.72 CALM1 (0.73) CALM1ALDH1A1LOXL2MAOBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723347-B2 Substituted phenylamino-pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-25 US disclosed
EP-1742945-B1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER SCHERING PHARMA AG (DE) 2009-12-30 EP disclosed
US-20080269268-A1 Substituted Phenylamino-Pyrimidines BAYER HEALTHCARE AG (DE) 2008-10-30 US disclosed
EP-1742945-A1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES Bayer HealthCare AG (DE) 2007-01-17 EP disclosed
WO-2005108397-A1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER HEALTHCARE AG (DE) 2005-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269268-A1 Substituted Phenylamino-Pyrimidines TYMP, DPYD, HPRT1 CALM1 1890/4885ALDH1A1 598/4885LOXL2 3179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.